Hemoximer

DB17600Investigational

Hemoximer is a modified version of hemoglobin that undergoes pyridoxylation, for the purpose of lowering the oxygen affinity, and coupling with polyoxyethylene (POE), to increase its molecular weight.

Mechanism: Pharmacologically active on Nitric oxide
Curator reviewed
Also known as: Pyridoxalated hemoglobin polyoxyethylene · Pyridoxalated-hemoglobin-polyoxyethylene conjugate
Code names: PHP

Resolves to

Compound

UNIIAE1041687F

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Hemoximer, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account